FDA Commissioner Marty Makary’s proposal to roll out a new drug approval pathway is heightening hope for the rare disease ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Amyotrophic lateral sclerosis has been a tough area for drug research ... Alchemab’s internal pipeline includes preclinical programs in development for Alzheimer’s, Parkinson’s, Huntington ...

Clinical trials for drug development are becoming increasingly complex, with numerous variables that must be identified and defined from the start. This complexity arises from rigorous study ...

Looking ahead, 2024 stands as the harbinger of a new era, where artificial intelligence not only streamlines existing processes, but also paves the way for novel methodologies in drug development.

As the leader in preclinical drug development, our long-standing mission is aligned with this vision as we continue to drive greater efficiency in the drug development process and reduce costs ...

John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. You’re reading the web ...

You can reach Allison on Signal at AllisonDeAngelis.01. In January, San Francisco’s Union Square was bustling with hordes of drug developers and investors, pounding the pavement on their way ...

Charles River Laboratories, a leading provider of preclinical drug development services, has reported impressive results in ...

Bethan Hughes investigates how the Chinese government's efforts to boost innovation have resulted in drug discovery ... at one potential compound for preclinical development.

His passion for drug development and prior PhD in the field of apoptosis/autophagy have helped him to translate pre-clinical experiences into early clinical trials. He designed and executed multiple ...